Gerry Hanna

Gerry Hanna: PET based inhomogenous dose escalation in stage 3 lung cancer

Gerry Hanna, Marie Curie Chair of Clinical Oncology at Trinity College Dublin, shared an article by Tine Schytte, et al. on X:

“Might PET based inhomogenous dose escalation be an approach to permit dose escalation in stage 3 lung cancer /NSCLC?

With modest toxicity rates and RT dose escation to median of 88.1 Gy to GTV, The phase 3 NARLAL2 trial suggests it may be RadOnc.”

Gerry Hanna: PET based inhomogenous dose escalation in stage 3 lung cancer

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non–Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial.

Journal: Journal of Clinical Oncology

Authors: Tine Schytte, et al.

Gerry Hanna: PET based inhomogenous dose escalation in stage 3 lung cancer

More posts featuring Gerry Hanna.

cancer clinical oncology fight against cancer Gerry Hanna Global fight against cancer inhomogenous Lung cancer NARLAL2 trial NSCLC OncoDaily Oncology RadOnc Trinity College Dublin